Oncology Market Expertise and Global Contacts   I  Accredited CME for Oncologists  I   Provider Number: CPDSO 50212

Skip to navigation Skip to content
Oncology Market Expertise
Oncology Commercial Services
  • Home
  • About
  • Engage Oncologists
  • Investors & Lenders
  • Market Access & BD
  • Distributors and manufacturers
  • International Market Entry
  • In/Out-licensing DD
  • Market Intelligence
  • Advisory Boards
  • Medical Education & Training
  • Recruitment
  • News
  • Contact
  • Home
  • About
  • Engage Oncologists
  • Investors & Lenders
  • Market Access & BD
  • Distributors and manufacturers
  • International Market Entry
  • In/Out-licensing DD
  • Market Intelligence
  • Advisory Boards
  • Medical Education & Training
  • Recruitment
  • News
  • Contact
  • Home
  • About
  • Engage Oncologists
  • Investors & Lenders
  • Market Access & BD
  • Distributors and manufacturers
  • International Market Entry
  • In/Out-licensing DD
  • Market Intelligence
  • Advisory Boards
  • Medical Education & Training
  • Recruitment
  • News
  • Contact

Tag: multiple-authors

Tag: multiple-authors

Repurposing heart drugs to target cancer cells

By Richard Hindle

A discussion of the potential to repurpose cardiac glycosides, currently used to treat cardiac arrythmias and atrial fibrillation, to treat cancer.

Read More

Metabolic reprogramming of branched-chain amino acid facilitates drug resistance in lung cancer

By Richard Hindle

Researchers have revealed the important role of epigenetic regulation-mediated metabolic reprogramming in lung cancer’s capacity to resist molecular targeted therapy.

Read More

Ovarian cancer cells stop moving when deprived of the protein Ran

By Richard Hindle

Researchers have shown the key role that a protein called Ran plays in the mobility of ovarian cancer cells. They demonstrated these cells cannot migrate from cancerous sites without the help of Ran.

Read More

Light therapy could replace opioids as main treatment for cancer treatment side effect

By Richard Hindle

A worldwide coalition of researchers and clinicians has agreed that light therapy is among the most effective interventions for the prevention of oral mucositis, painful ulcers in the mouth resulting from cancer therapy.

Read More

Discovery of mechanism behind precision cancer drug opens door for more targeted treatment

By Richard Hindle

New research that uncovers the mechanism behind the newest generation of cancer drugs is opening the door for better targeted therapy.

Read More

Scientists discover origin of cell mask that hides stomach cancer

By Richard Hindle

A layer of cells that look like normal stomach lining on top of sites of stomach cancer can make it difficult to spot after removal of a Helicobacter pylori infection.

Read More

Biliary microbiome altered after neoadjuvant therapy for pancreatic cancer

By Richard Hindle

The biliary microbiome – the collection of bacteria present in the bile ducts – was altered in patients who received neoadjuvant therapy prior to undergoing surgery for pancreatic cancer.

Read More

New probe could help surgeons more accurately remove tumours

By Richard Hindle

A study led by researchers at RCSI’s Department of Chemistry has the potential to help surgeons more accurately remove tumours and detect cancer in lymph nodes during surgery.

Read More

Researchers identify effective drug combination against uveal melanoma

By Richard Hindle

Researchers have identified a new drug combination that is effective against metastatic uveal melanoma cells in preclinical studies.

Read More

Natural antioxidant helps improve immune-based therapies by modulating T-cells

By Richard Hindle

Researchers have discovered a way to improve immune-based treatments, such as adoptive T-cell therapy (ACT) and haematopoietic stem cell transplantation (HSCT), by modulating T-cells with thioredoxin, a powerful, naturally occurring antioxidant molecule.

Read More

Posts pagination

  • Previous
  • 1
  • …
  • 3
  • 4
  • 5
  • …
  • 10
  • Next
Recent Posts
  • Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor
  • Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?
  • Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume
  • Daiichi Sankyo and AstraZeneca does a Batman & Robin act and fires off its second ADC shot of 2024 with another FDA BLA for Dato-DXd
  • Is it time for PET-guided therapy in follicular lymphoma?
×

Error: Contact form not found.

Back To Top

  • Home
  • Team
  • Advisory Services
  • Market Intelligence Services
  • Recruitment
  • Contact
  • Market Access / BD
  • CME Learner Resources
  • CME Evaluation Form
  • Help Centre
  • Contact
  • Disclaimers
  • Privacy & GDPR Policy
  • Website Accessibility Policy
  • Equal Opportunities Policy and Learning Charter
  • Complaints Policy
  • Contact
© Oncology Commercial Services 2025
Built with Storefront.

Copyright 2024  Oncology Commercial Services. All Rights Reserved. Fratrem Group Ltd, Company number 08002465